MarketLens
Sign Up

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

3 months ago
SHARE THIS ON:

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV Combinations

TaiMed Biologics reported Phase 1 data at IDWeek 2026 showing TMB-365 antiviral activity and tolerability, supporting continued development as a differentiated antibody for combination HIV treatment. ...
Stock News•1 months ago

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

Gilead and PAHO agreed to expand access to lenacapavir for HIV prevention across 14 Latin American countries, a move AHF called a victory for civil society after early mobilization over access concern...
Stock News•3 months ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Gilead and Merck's once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for the first weekly regimen.

Breaking News

View All →

Top Headlines

View More →
Stock News•20 minutes ago

House G.O.P. Leaders Ask Nvidia's Huang to Speak in Closed-Door Briefing

Stock News•1 hour ago

Stock Market Today, Nov. 5: Amazon Shares Slide as Technology Selloff Erases Early Gains

Stock News•1 hour ago

Google, Meta and TikTok Sue California Over Ban on Features for Kids

Stock News•2 hours ago

Market Close: Stocks Tumble, Apple To Sell $7B In Debt, Wendy's Rejects Buyout Bid 11-5-2026

Stock News•2 hours ago

Stock Market Today, Nov. 5: Nvidia Slides on AI Chip Selloff as Election Uncertainty Weighs